1. Introduction {#sec1}
===============

Commonly accepted, bladder cancer (BC) pertains to a malignant tumor with top incidence in urological diseases \[[@B1]\]. Overall, bladder tumors are commonly in the presence of noninvasive urothelial carcinoma and muscle-invasive disease \[[@B2]\]. The invasive subtype of BC is closely associated with metastatic spread and poor prognosis of patients \[[@B3]\]. Despite great advances made in the diagnosis and treatment of BC, therapeutic options are limited and prognosis remains unfavorable \[[@B4], [@B5]\]. Therefore, elucidating the underlying molecular mechanism of development and progression is conductive to and even decisive on BC treatment.

The application of Chinese traditional medicine in tumor treatment has gained much attention in recent years \[[@B6]--[@B8]\]. Melittin with twenty-six amino acids is the essential component of honeybee venom \[[@B9]\]. Prior research generally confirms that honeybee venom is accepted as Chinese medicine and applied for treatment of various diseases, exemplified by arthritis, rheumatism, back pain, cancer, and skin disease \[[@B10]\]. Intriguingly, discussions regarding melittin associated with diverse cancers have dominated research in recent years. In our previous work, we retrieved and analyzed articles from 2010 to now in the PubMed database with the search keyword of melittin and cancer. We found that melittin could induce apoptosis and constrain the progression of tumor cells as a result of regulating critical cancer-related signaling pathways. For example, Jo et al. unveiled that melittin could have an anticancer effect as a result of inducing apoptotic cell death in ovarian cancer through enhancement of death receptors and suppression of the JAK2/STAT3 signaling pathway \[[@B11]\]. A similar anticancer effect in prostate cancer cells was evidenced and materialized through activation of the caspase pathway via inactivation of NF-*κ*B \[[@B12]\]. It has also been reported that melittin could suppress PMA-induced tumor cell invasion by inhibiting NF-*κ*B- and AP-1-dependent MMP-9 expression \[[@B13]\], probably through JNK/p38- and NF-*κ*B-dependent mechanisms \[[@B14]\]. Jeong et al. outlined that melittin suppresses TNF-*α*-induced HASMC migration through the selective inhibition of MMP-9 expression \[[@B15]\]. Shin et al. illustrated that melittin could hold down HIF-1*α*/VEGF expression through inhibition of the ERK and mTOR/p70S6K pathway in human cervical carcinoma cells \[[@B16]\]. Jeong et al. probed that melittin could constrain EGF-induced MMP-9 expression via blocking the NF-*κ*B and PI3K/Akt/mTOR signaling pathway and repress EGF-induced FAK phosphorylation through inhibiting the mTOR/p/0S6K/4E-BP1 signaling pathway in breast cancer cells \[[@B17]\]. Kong et al. proffered the conclusion of melittin exerting a positive role in gastric cancer cell apoptosis via activation of the mitochondrial pathway \[[@B18]\]. Furthermore, the antitumor activity of melittin was reported to be associated with antiangiogenic actions via inhibiting VEGFR-2 and inflammatory mediators involved in the MAPK signaling pathway \[[@B19]\] or to suppress hepatic epithelial-to-mesenchymal transition via blocking of TGF*β*/Smad and MAPK-JNK signaling pathways \[[@B20]\]. As recently reported, it was demonstrated that melittin could constrain tumor angiogenesis modulated by endothelial progenitor cells involved in the SDF-1*α*/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model \[[@B21]\]. However, little was known about the association between melittin and BC, which promoted us to conduct this study.

Popularly accepted, the Gene Expression Omnibus (GEO) accessible at [www.ncbi.nlm.gov/geo](http://www.ncbi.nlm.gov/geo) is a public repository that archives and freely distributes high-throughput gene expression data submitted by the scientific community. Huge volumes of data including individual gene expression, multifarious organisms, and a wide range of biological issues could be effectively explored, queried, and visualized by means of user-friendly web-based tools. In recent years, microarrays contingent on high-throughput platforms have emerged as a promising and efficient tool for screening significant genetic or epigenetic alternations in carcinogenesis and identifying promising biomarkers for diagnosis and prognosis of cancers \[[@B22]\]. Plentiful gene expression profiling microarrays have been employed to identify multifarious differentially expressed genes (DEGs) in various cancers, and a number of BC-related DEGs have therefore been documented \[[@B23]--[@B25]\]. Nonetheless, various additional critical genes and pathways associated with BC remain yet to be explored completely.

In the present study, we aimed to disclose the crucial genes associated with BC and investigate the effect of melittin on the identified crucial genes in BC. On the one hand, the transcription profile of GSE35014 was downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35014>) and data processing was performed using R software (version 3.3.0, available online: <https://www.r-project.org/>) and bioconductor packages (available online: <http://www.bioconductor.org/>), together with the online website Database for Annotation, Visualization, and Integrated Discovery (DAVID; version 6.8). Differentially expressed genes (DEGs) were screened in BC cells and control. Gene ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and protein--protein interaction (PPI) network analysis were employed to evaluate the crucial genes and signaling pathways involved in BC. On the other hand, we collected melittin-related articles involved in cancers from the PubMed database and analyzed the relationship between melittin and various cancers that have been reported. After that, we combined the KEGG, PPI network, and module analyses intersecting with the literature analysis to obtain our target signaling pathway and crucial DEGs. The data analysis pipeline for key genes in BC is displayed in [Figure 1](#fig1){ref-type="fig"}. Finally, we investigated the effect of melittin on the critical DEG expression in BC cells and its functional role in proliferative and migrated abilities of BC separately by qRT-PCR and functional assays. By this token, these critical DEGs and signaling pathways identified in this work would convey valuable information about the mechanism of BC carcinogenesis and expose the discovery of key genes that may act as future targets of anticancer therapy.

2. Materials and Methods {#sec2}
========================

2.1. Dataset Collection and Identification of DEGs in BC {#sec2.1}
--------------------------------------------------------

Microarray technology becomes widely accepted as a high-throughput tool for measuring gene expression \[[@B26]\]. As previously reported, data from DNA microarray analysis plays a reliable and useful role in identifying novel targets for clinical diagnostic and therapeutic approaches \[[@B27], [@B28]\]. The selection criteria of datasets in our work were described as follows: (1) associated with BC cells, (2) focus on the invasion and metastasis of BC, (3) sample size no less than 4, and (4) based on the GPL570 platform. Extracted from the GEO (<https://www.ncbi.nlm.nih.gov/geo/>) database, one microarray expression profile termed GSE35014 was therefore employed to identify DEGs associated with BC (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35014>). The microarray data of GSE35014 was contingent on GPL570 platforms (Affymetrix Human Genome U133 Plus 2.0 Array, Affymetrix Inc., Santa Clara, CA, USA). It has been reported that UM-UC-3 bladder carcinoma cells have lost the endogenous expression of Rho GDP dissociation inhibitor 2 (RhoGDI2), as occurs commonly in the progression of BC \[[@B29]\]. In this query, two paired biological replicates of GFP (control) and GFP-RhoGDI2 (experimental) UM-UC-3 cells were constructed at different times, isolated during log phase growth, and subjected to gene expression profiling by means of the Affymetrix HG-U133 Plus 2.0 oligonucleotide microarray platform.

R software (version 3.3.0; <https://www.r-project.org/>) and bioconductor packages (available online: <http://www.bioconductor.org/>) were applied for data mining and statistical analyses. Concretely, the original annotation file and CEL files of the Affymetrix platform were firstly downloaded. Limma package \[[@B30]\] was applied to identify DEGs between experimental and control groups with the cut-off criterion of *P* \< 0.05 and absolute log2 FC \> 1.

2.2. GO and KEGG Enrichment Analyses in BC {#sec2.2}
------------------------------------------

With regard to the investigation of potential biological functions of DEGs in BC, GO \[[@B31]\] functional and KEGG \[[@B32]\] pathway analyses were conjointly carried out. The DAVID online tool available at <https://david.ncifcrf.gov/> was applied for these analyses. Significantly enriched GO terms and KEGG pathways were screened out as a criteria of *P* \< 0.05, finally visualized using R package ggplot2 \[[@B33]\].

2.3. PPI Network Construction {#sec2.3}
-----------------------------

Search Tool for the Retrieval of Interacting Genes (STRING) accessible at <http://string-db.org/> is an online database which includes experimental data and computational prediction methods as well as public text collections, involved in beyond 1100 completely sequenced organisms \[[@B34]\]. The protein interactions in the STRING database were presented as a combined score. The STRING database system was used to construct the functional protein association networks. Interacting pairs with a combined score more than 0.8 were considered to be significant and employed to construct networks. Cytoscape (<http://www.cytoscape.org/>) \[[@B35]\] was disseminated to visualize these networks.

2.4. MCODE Analysis {#sec2.4}
-------------------

Molecular Complex Detection (MCODE; <https://omictools.com/molecular-complex-detection-tool>) could be applied to evaluate densely connected regions in large PPI networks possibly involved in molecular complexes \[[@B36]\]. MCODE was disseminated to mine the core protein complex in the PPI network constructed in this work.

2.5. Cell Culture and Treatment {#sec2.5}
-------------------------------

The human BC cell lines T24 and 5637 were purchased from the American Type Culture Collection (ATCC; Manassas, VA). Cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Grand Island, NY, USA) and 100 U/ml of penicillin/streptomycin. The cultured cells were maintained at 37°C in a humidified atmosphere with 5% (*v*/*v*) CO~2~. Cells were plated in 24-well plates (5 × 10^4^ cells/well), and subconfluent cells were treated with melittin at a concentration of 0 and 4 *μ*g/ml for 24 h, respectively. Melittin used in this work was purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.6. Real-Time Quantitative PCR Validation {#sec2.6}
------------------------------------------

Total RNA was extracted from treated cells using the TRIzol reagent (Life Technologies, California, USA) according to the manufacturer\'s instructions. 1 *μ*g of the total RNA was withdrawn and used as the template for cDNA synthesis using a PrimeScript RT Reagent Kit with cDNA Eraser (Takara Biotech, Dalian, China). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed by using SYBR Premix Ex Taq (Takara Biotech, Japan) on an ABI 7900 system (Applied Biosystems, Foster City, CA, USA). The primers used in this work are presented in [Table 1](#tab1){ref-type="table"}. The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The quantification of gene expression was calculated using a relative quantification method (2^−ΔΔCt^).

2.7. Cell Proliferation Assays {#sec2.7}
------------------------------

After treatment with melittin (0 and 4 *μ*g/ml), cell proliferation was assessed by the MTS assay (Promega, Madison, US) according to the manufacturer\'s protocol. 5637 and T24 cells (2000 cells per well) in each group were plated in 96-well plates. Twenty microliters of the MTS reagent was added to each well containing 100 *μ*l of culture medium. The plate was incubated for 2 h at 37°C in a humidified atmosphere with 5% (*v*/*v*) CO~2~. The plate was then read at 490 nm using a plate reader.

2.8. Cell Migration Assays {#sec2.8}
--------------------------

The scratch wound-healing assay was employed to examine cell migration. Uniform wounds were scraped in 5637 and T24 cells grown on plastic 6-well plates using a pipette tip before transfection. The initial gap length (0 h) and the residual gap length (48 h) after wounding were calculated from photomicrographs.

2.9. Statistical Analysis {#sec2.9}
-------------------------

Each experiment was repeated three times, and all values were presented as the means ± standard deviation (SD). The *t*-test was employed to analyze the difference in two groups. GraphPad Prism software version 5.0 was applied to complete statistical analysis. A value of *P* \< 0.05 was considered statistically significant in this work.

3. Results {#sec3}
==========

3.1. Identification of DEGs in BC {#sec3.1}
---------------------------------

According to microarray analysis, a total of 558 DEGs were achieved to be differentially expressed with a fold change \> 2 between the BC cell group and control, as revealed in [Figure 2](#fig2){ref-type="fig"}. Among them, 389 upregulated and 169 downregulated genes were separately obtained as listed in [Table 2](#tab2){ref-type="table"}. These DEGs were employed for follow-up analyses.

3.2. GO Enrichment Analysis {#sec3.2}
---------------------------

Commonly, GO functional enrichment analysis is involved in biological process, molecular function, and cellular component. In this study, GO functional enrichment analysis of DEGs was performed by means of an online biological tool DAVID with a threshold of *P* \< 0.05. Top thirty significant GO terms according to *P* value are visualized and displayed in [Figure 3](#fig3){ref-type="fig"}, and corresponding related DEGs are summarized in [Table 3](#tab3){ref-type="table"}. It could be materialized that a sum of DEG-enriched terms play a critical role in the biological behavior of tumor cells. Most of the DEGs were significantly enriched in protein binding, plasma membrane, extracellular space, and signal transduction. Concretely, in terms of biological process, DEGs were principally enriched in signal transduction, cell adhesion, and positive regulation of cells, while they are concentrated in the plasma membrane, extracellular space, and cell surface with respect to cellular component. As for molecular function, DEGs focused on the relation with protein binding, actin binding, and heparin binding.

3.3. Signaling Pathway Enrichment Analysis {#sec3.3}
------------------------------------------

Pathway analyses were used to identify the significant pathways associated with the DEGs according to KEGG analysis. As mentioned in GO analysis, the online biological tool DAVID with a threshold of *P* \< 0.05 was also applied in this section. Top fifteen significant pathways were visualized by R package ggplot2. As depicted in [Figure 4](#fig4){ref-type="fig"} and [Table 4](#tab4){ref-type="table"}, DEGs were essentially abundant in cancer-related pathways, such as pathways in cancer (ID: hsa05200), PI3K-Akt signal pathway (ID: hsa04151), cytokine-cytokine receptor interaction (ID: hsa04060), focal adhesion (ID: hsa04510), cell adhesion molecules (ID: hsa04514), transcriptional misregulation in cancer (hsa05202), Jak-STAT signal pathway (ID: hsa04630), and TNF signaling pathway (ID: hsa04668), which all play a critical and even decisive role in the progression and development of tumors.

3.4. Identification of Key Candidate Genes and Signaling Pathways Based on PPI Network and Modular Analyses {#sec3.4}
-----------------------------------------------------------------------------------------------------------

With the purpose of systemically analyzing the functions of DEGs in BC, these DEGs were mapped to PPI data dependent on the STRING online database (available online: <http://string-db.org>) and Cytoscape software (version 3.4.0, available online: <http://www.cytoscape.org/>). Interacting pairs with a combined score more than 0.8 were considered to be significant and employed to construct networks. The PPI network with 309 interacting pairs was thus obtained ([Figure 5(a)](#fig5){ref-type="fig"}), which also was provided as Supplementary Material ([available here](#supplementary-material-1){ref-type="supplementary-material"}) for zooming in and out as needed. Based on the PPI network, we subsequently analyzed the network clusters by MCODE, and twelve module networks were therefore generated as described in [Table 5](#tab5){ref-type="table"}. The module networks with a score no less than 4 were selected for the next analysis and are depicted in [Figure 5(b)](#fig5){ref-type="fig"}. Fifteen module-related DEGs marked as bold in [Table 4](#tab4){ref-type="table"} were thus obtained, including CXCL2, CXCL1, BDKRB1, LPAR1, CXCL3, FYN, COL6A2, COL18A1, COL13A1, COL5A1, TUBA1A, FDFT1, SQLE, LSS, and CDK9. Combined with Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}, it could be found that the signaling pathways associated with these module-related DEGs were described as follows: pathways in cancer (ID: hsa05200), PI3K-Akt signaling pathway (ID: hsa04151), focal adhesion (ID: hsa04510), transcriptional misregulation in cancer (ID: hsa05202), TNF signaling pathway (ID: hsa04668), Gap junction (ID: hsa04540), protein digestion and absorption (ID: hsa04974), and steroid biosynthesis (ID: hsa00100).

3.5. Melittin Constrained the Expression of the Module-Related DEGs Associated with PI3K-Akt and TNF Signaling Pathways in BC Cells {#sec3.5}
-----------------------------------------------------------------------------------------------------------------------------------

According to literature analysis, we found that the signaling pathways associated with melittin in cancers mainly include JAK2/STAT3, NF-*κ*B, JNK/p38/NF-*κ*B, TNF-*α*, mTOR/p70S6K or mTOR/p/0S6K/4E-BP1, PI3K/Akt/mTOR, mitochondrial pathway, MAPK signaling pathway, TGF*β*/Smad and MAPK-JNK signaling pathways, and SDF-1*α*/CXCR4 signaling pathway so far \[[@B11]--[@B21]\]. JAK2/STAT3, TNF-*α*, mTOR/p70S6K or mTOR/p/0S6K/4E-BP1, and PI3K/Akt/mTOR signaling pathways represented above were in accordance with the signaling pathway IDs of hsa04630, hsa04668, hsa04150, and hsa04151 as shown in [Table 4](#tab4){ref-type="table"}. The module-related DEGs in the PI3K/Akt (namely, LPAR1, COL5A1, and COL6A2) and TNF signaling pathway (termly CXCL1, CXCL2, and CXCL3) were selected to investigate the effect of melittin on them in BC cells. As revealed in [Figure 6](#fig6){ref-type="fig"}, it was clear that the expressions of LPAR1, COL5A1, and COL6A2 associated with the PI3K/Akt signaling pathway were significantly decreased in cells treated with melittin compared to the control. So was the case in the expressions of CXCL1, CXCL2, and CXCL3 involved in the TNF signaling pathway. Collectively, our findings demonstrated that melittin could constrain the expression of the module-related DEGs associated with PI3K-Akt and TNF signaling pathways in BC cells.

3.6. Melittin Suppressed Cell Proliferation and Migration in BC Cell Lines {#sec3.6}
--------------------------------------------------------------------------

As previously reported, melittin could have an inhibitory effect on cell motility and migration through PI3K/Akt and TNF signaling pathways in diseases \[[@B15], [@B17]\]. We therefore investigated the effect of melittin on cell proliferation and migration in 5637 and T24 cell lines by MTS and scratch wound-healing assays. Results obtained showed that cell viabilities were significantly inhibited in the melittin-treated group (4 *μ*g/ml) in comparison with the control group (0 *μ*g/ml) according to the MTS assay (Figures [7(a)](#fig7){ref-type="fig"} and [7(b)](#fig7){ref-type="fig"}, *P* \< 0.05). Similar results were also obtained in the effect of melittin on cell migration as analyzed by the scratch wound-healing assay (Figures [7(c)](#fig7){ref-type="fig"} and [7(d)](#fig7){ref-type="fig"}, *P* \< 0.05). Taken together, melittin could induce a significant reduction in proliferation and migration of BC cells.

4. Discussion {#sec4}
=============

As we know, melittin with twenty-six amino acids is the essential component of honeybee venom \[[@B9]\]. Current available literature including in vitro and in vivo studies suggests that melittin governs signal transduction and regulatory pathways associated with multiple cancer death mechanisms, including inhibition of proliferation, induction of apoptosis, inhibition of angiogenesis, cell cycle arrest, and inhibition of cancer motility, migration, metastasis, and invasion \[[@B37]\]. The melittin-related cancers reported consist of leukemia \[[@B38]\], lung carcinoma mouse model \[[@B39]\], pancreatic ductal adenocarcinoma \[[@B40]\], hepatocellular carcinoma cells \[[@B41]\], ovarian cancer cells \[[@B11]\], and so forth. However, little was known about the association between melittin and BC. Melittin and bladder cancer were set as search keywords in the PubMed database, and only three related articles were obtained \[[@B42]--[@B44]\]. It was worth noting that the associated signaling pathways involved in melittin regulating BC also remained yet to be completely elucidated.

In the present work, a genome-wide survey and literature search were therefore conjunctively employed to identify the potential key genes and signaling pathways associated with melittin in BC. 389 upregulated and 169 downregulated DEG genes were obtained according to dataset analysis contingent on high-throughput platforms, enriching the document of BC-related DEGs now available. GO \[[@B31]\] functional enrichment analysis evidenced that most of the DEGs were significantly enriched in protein binding, plasma membrane, extracellular space, and signal transduction. KEGG \[[@B32]\] analysis surfaced that DEGs were essentially abundant in pathways in cancer, PI3K-Akt signal pathway, Jak-STAT signal pathway, TNF signaling pathway, and mTOR signaling pathway. We noted that JAK2/STAT3 \[[@B11]\], TNF-*α* \[[@B15]\], mTOR/p70S6K or mTOR/p/0S6K/4E-BP1 \[[@B16]\], and PI3K/Akt/mTOR \[[@B17]\] signaling pathways associated with melittin in cancers were in accordance with the signaling pathway IDs of hsa04630, hsa04668, hsa04150, and hsa04151. Ulteriorly, fifteen module-related DEGs were obtained according to PPI network and modular analyses with a score no less than 4, namely, CXCL2, CXCL1, BDKRB1, LPAR1, CXCL3, FYN, COL6A2, COL18A1, COL13A1, COL5A1, TUBA1A, FDFT1, SQLE, LSS, and CDK9. Combining KEGG with module analysis, the module-related DEGs corresponding to signaling pathways were described as follows: SQLE, LSS, and FDFT1 for steroid biosynthesis (ID: hsa00100); LPAR1 and TUBA1A for gap junction (ID: hsa04540); CDK9 for transcriptional misregulation in cancer (ID: hsa05202); CXCL1, CXCL3, and CXCL2 for the TNF signaling pathway (ID: hsa04668); COL18A1, COL13A1, COL6A2, and COL5A1 for protein digestion and absorption (ID: hsa04974); LPAR1, COL5A1, and COL6A2 for the PI3K-Akt signaling pathway (ID: hsa04151); COL5A1, FYN, and COL6A2 for focal adhesion (hsa04510); and BDKRB1 and LPAR1 for pathways in cancer (ID: hsa05200). It was clear that the PI3K-Akt (ID: hsa04151) and TNF signaling pathways (ID: hsa04668) associated with melittin contained the module-related DEGs in combination of literature and bioinformatic analyses. The module-related DEGs contained in these two signaling pathways were thus selected for further work. The effect of melittin on their contained module-related DEGs, LPAR1, COL5A1, COL6A2, CXCL1, CXCL2, and CXCL3, was subsequently analyzed in BC cells. In fact, some of these module-related DEGs have been reported to be significantly correlated with the occurrence and development of BC, which were exemplified as follows. Zhang et al. reported that the CXCL2-associated signaling pathway, CXCL2/MIF-CXCR2, could advance the recruitment of myeloid-derived suppressor cells and be identified as predictors and potential therapeutic targets in BC patients \[[@B45]\]. CXCL1 as a potential mediator and marker of the tumor invasion of BC was elevated in the urine of BC patients \[[@B46], [@B47]\]. CXCL1 and CXCL3 related to the nuclear factor kappa B and nuclear factor (erythroid-derived 2)-like 2 signaling pathways were measured in human urothelial carcinoma cell lines \[[@B48]\]. Expression changes of COL3A1 and COL5A1 as the fibrillar collagen proteins were associated with muscle-invasive bladder transition cell carcinoma \[[@B49]\]. Our results showed that these module-related genes were downregulated in cells treated with melittin compared to the control, indicating that melittin could constrain the expression of the module-related DEGs associated with PI3K-Akt and TNF signaling pathways in BC. This further highlights that these genes might be drug-sensitive markers for melittin in BC treatment. As previously reported, melittin exerts an antitumor effect on non-small-cell lung cancer cells \[[@B50]\] and suppresses EGF-induced cell motility and invasion in breast cancer cells \[[@B17]\]. In our work, the functional assays conveyed the prohibitive role of melittin in proliferative and migrated abilities of BC cell lines. This may be the first evidence regarding the initiatory role of melittin in BC metastasis.

To conclude, our findings conveyed valuable information about the mechanism of BC carcinogenesis and expose the discovery of key genes that may act as future targets of anticancer therapy. However, only preliminary verification was conducted regarding the effect of melittin on the expression of the key genes in BC cells in this work, and further investigation remains yet to be elucidated. Therefore, the functional role and concrete mechanism of melittin on the crucial genes in BC would move forward in our next plan on the basis of this work.

5. Conclusions {#sec5}
==============

In this work, we identified 558 candidate DEGs and most of them were significantly enriched in protein binding, plasma membrane, extracellular space, and signal transduction. Fifteen module-related DEGs were obtained, and melittin could constrain the expressions of LPAR1, COL5A1, and COL6A2 associated with the PI3K-Akt signaling pathway and CXCL1, CXCL2, and CXCL3 involved in the TNF signal pathway in BC cells. We also found that melittin could induce a significant reduction in proliferation and migration of BC cells. These findings provide a theoretical basis for these six genes as drug-sensitive markers of melittin in BC treatment.
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###### 

The PPI network was clearly shown in the Supplementary Material for zooming in and out as needed. The larger the node diameter is, the smaller the *P* value and the more significant the node is.

###### 

Click here for additional data file.

![Data analysis pipeline for key genes in BC. DEGs: differentially expressed genes; GO: gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; PPI: protein--protein interaction; BC: bladder cancer.](JIR2018-5038172.001){#fig1}

![Volcano plot of detectable DEG profiles in BC cells. Red plots stand for upregulated genes, and blue ones represent downregulated genes with *P* \< 0.05 and absolute log~2~FC \> 1. Black ones indicate those nonsignificant expressed genes. The abscissa means the value of fold change in circulating the gene expression between BC cells and control. The ordinate shows the −log~10~ of the adjusted *P* value for each gene, suggesting the strength of the association. DEGs: differentially expressed genes; BC: bladder cancer; FC: fold change.](JIR2018-5038172.002){#fig2}

![Top thirty significant enriched GO terms of DEGs in BC according to their functions. GO: gene ontology; BP: biological process; MF: molecular function; CC: cellular component; DEGs: differentially expressed genes; BC: bladder cancer.](JIR2018-5038172.003){#fig3}

![Top fifteen significant pathways associated with the DEGs according to *P* value in KEGG analysis. KEGG: Kyoto Encyclopedia of Genes and Genomes; DEGs: differentially expressed genes.](JIR2018-5038172.004){#fig4}

![PPI network constructed by Cytoscape and top seven module networks by MCODE. (a) The PPI network was constructed dependent on the STRING online database (available online: <http://string-db.org>) and Cytoscape software (version 3.4.0, available online: <http://www.cytoscape.org/>). (b) The top seven module networks with a score no less than 4 were analyzed by MCODE. The red nodes stand for upregulated genes, and the green nodes stand for downregulated genes. The larger the node diameter is, the smaller the *P* value and the more significant the node is. PPI: protein--protein interaction; MCODE: Molecular Complex Detection; STRING: Search Tool for the Retrieval of Interacting Genes.](JIR2018-5038172.005){#fig5}

![The expressions of the module-related DEGs associated with PI3K-Akt and TNF signaling pathways were detected in T24 cells treated with melittin by qRT-PCR. DEGs: differentially expressed genes. ^∗^ *P* \< 0.05 and ^∗∗^ *P* \< 0.01.](JIR2018-5038172.006){#fig6}

![Melittin suppressed cell proliferation and migration in 5637 and T24 cell lines. (a) 5637 and (b) T24 cell viabilities were significantly inhibited in the melittin-treated group (4 *μ*g/ml) in comparison with the control group (0 *μ*g/ml) as determined by the MTS assay. (c) 5637 and (d) T24 cell migration was remarkably constrained in the melittin-treated group (4 *μ*g/ml) in comparison with the control group (0 *μ*g/ml) as analyzed by the scratch wound-healing assay. Magnification ×100. OD: optical density. ^∗^ *P* \< 0.05 and ^∗∗^ *P* \< 0.01.](JIR2018-5038172.007){#fig7}

###### 

The primers for qRT-PCR analysis were applied in this work.

  Genes     Orientation                  Sequences (5′--3′)
  --------- ---------------------------- --------------------------
  LPAR1     Forward                      GGCTGCCATCTCTACTTCCATCC
  Reverse   ACAAACAGTGATTCCAAGTCCCA      
  COL5A1    Forward                      ATCTTCGGCTCTCTCAACTCTC
  Reverse   GTCCACATAGGAGAGCAGTTTC       
  COL6A2    Forward                      AGCCTACGGAGAGTGCTACAAG
  Reverse   TGTCCATCGGTCCCGTTCTTGC       
  CXCL1     Forward                      AACCGAAGTCATAGCCACA
  Reverse   TCCTAAGCGATGCTCAAA           
  CXCL2     Forward                      CAAACCGAAGTCATAGCC
  Reverse   GAACAGCCACCAATAAGC           
  CXCL3     Forward                      CAAACCGAAGTCATAGCC
  Reverse   ACCCTCGTAAGAAATAGTCA         
  GAPDH     Forward                      TCCTCACAGTTGCCATGTAGACCC
  Reverse   TGCGGGCTCAATTTATAGAAACCGGG   

###### 

The DEGs in GEO data were identified in BC samples.

                       Gene names
  -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated DEGs     MAN1A1, ARHGDIB, PDE1A, SLC1A1, RNF182, CXCL1, ABLIM1, NEFL, GRAMD3, GJA1, TENM2, CFH, BDKRB1, CA8, HAS2, PTCHD1, STC1, NECTIN3, DNER, MARCKS, TRIM6, SYTL2, ARL4C, WNT5A, VCAM1, VEGFC, KLF12, NLGN1, LMO4, TNS3, ATXN1, LRRC15, CLEC2B, HHIP, TMEM45A, DAPK1, EPB41L3, ADGRG6, ENPP2, MLPH, TUBAL3, RUNX2, TMEM200A, EDN1, PAG1, DIXDC1, TCF4, IL1RAPL1, INHBB, ADAM12, EPS8, CNTN1, MYLK, G0S2, EFNA5, TMEM56, MMP2, TBC1D4, SLC16A2, LOXL2, RORA, SLC8A1, GDA, PAQR5, BHLHE41, RCAN3, ADAMTS5, TMEM158, ADAMTS12, DDIT4, DPP7, SNAI2, TENM3, C4orf47, PPARG, DPYSL2, PID1, C15orf48, CXCL3, CLU, FYN, PTGER4, TMPRSS15, CA12, CXCL8, BNIP3L, TFPI2, FBXL7, LRFN5, CHST4 SH3RF3, PDK3, PLPP3, P4HA2, PGM5, TSC22D1, FAM102B, TMEM44, GABBR2, GUCY1A2, NR5A2, MID1, CCL2, AKR1C3, MAP3K7CL, PXDNL, GCNT1, VLDLR, C11orf96, LOC283352, RNASE4, BASP1, PHACTR1, TGFBI, KLF6, HMOX1, ANXA3, SAT1, SLC39A4, ID2, SSBP2, PRUNE2, SLC1A3, AFP, NR2F1-AS1, RGS4, ANG, NDRG1, SLC25A30, NRN1 PFKFB4, ST3GAL5, TSC22D3, PXK, PRKCDBP, MYBL1, TMCO3, CTSB, NREP, PRICKLE2, NKX3--1, PPM1E, MAP1B, CD99, ITGA4, DDR2, SDC2, TUBB2A, CELF2, KANK1, EYA1, CCDC134, ALDH3B1, DPYSL4, IER3, MAP4K4, ATP8B3, LIFR, ARFGEF3, FOSL2, CAV1, NANOS1, KCNN4, PPP1R16A, SAP30, EPAS1, KCTD21, PBX1, TLE4, MICAL3, SIM1, PMEPA1, TAF9B, SMAD6, JUND, PDGFC, FPR1, GYS1, LSS, MXI1, CCDC92, IDH2, RRAS, AAMDC, CXCL2, RIPK4, DPY19L2P2, PEG10, DHRS3, ALDH1A1, MICAL2, CXXC5, DKK3, SELENOM, TCF7L1, IRS1, RFX5, TMSB4X, DCAF6, PRR16 STXBP6, CERK, PTTG1IP, ELL2, LINC00643, LACTB, ZNF385D, LTBP1, CAT, P2RY8 SNAPC3, SYNC, IL31RA, FAM229B, 3\\Mar, ATP2B4, RASSF2, DNAJB4, SLC39A10, CUEDC1 LINC00165, MTHFD2L, RIMS3, TXNDC16, C10orf10, NAT1, PLEKHG4, GLCCI1, PIK3R3, LOC286161, NID2, CXADR, TNC, TUBA1A, GSTM4, LOC100506844, OGFRL1, FDFT1, CACNA1A, HERPUD2, CD109, PNRC1, PLIN2, SEC22C, GRK5, DHCR7, RRAGA, KDM4C, DPYSL5, MRGPRX3, CDH2, FAM127B, ANKRD20A5P, FAM127A, IL11RA, PPP4R4, MME, MGST3, LOC101927752, FAM168A, CDYL2, PPP1R3C, ZNF827, CCBE1, MSMO1, TM4SF1, P3H2, NCAM2, YPEL5, PTPRS, INSIG1, CDC42EP3, TCFL5, IL1R1, PRICKLE1, LGALS1, CPEB2, LOC105371967, TRIQK, SCD, FAM134B, LPAR1, GFPT2, COL13A1, FAM133A, F2R, TUSC1, CA9, ENO2, VEGFA, PLAU, KIF3C, KATNAL1, OPTN, FABP4, PDE8A, LOC283140, ADD3, SQLE, COL18A1, INSIG2, TADA3, TMEM170B, ATL1, CCL7, IGSF3, NEURL1B, CHI3L2, COL6A2, CHKB, PAPPA, TGIF1, HTRA1, TBC1D8B, ASAH1, ABCC10, MSC-AS1, VMP1, LOC101927027, IL18, LPCAT2, MYO9A, FLI1, KLF13, HBP1, PRR34-AS1, DHCR24, MGLL, GLCE, CCNG2, TTC13, MOSPD2, LOC100506922, ROBO2, ZNF697, HDAC4, MLF1, CSMD3, CCNA1, SCO2, SLC25A1, BNC2, ZNF704, CD82, PICSAR, FOXP4-AS1, FAM110B, SPAG4, RECK, CLDN1, SH3PXD2A, SNTB1, IRF9, LACC1, EPHX1, WWC3, THAP8, RIMS2, SREBF2, TMOD2, ZNF365, ARHGAP28, COL5A1, IFT74, LOC100130987, LINC01279, SPRY1, PQLC2L, CADM1, C11orf80, MIR210HG, PPP1R13L, KIAA0895, NRP1, PLSCR4, HGSNAT, KRCC1, HIST1H2AC, GPR137C, TNFAIP8, IQGAP3, WIPF1, URB1-AS1, IL17RD, MBD5, REEP6, ANK2, PQLC3, DNAJC6.
                       
  Downregulated DEGs   PTPRD, VCAN, HAPLN1, JPH1, DSP, CA2, ZNF804A, ETV1, MTUS1, GULP1, ZNF268, KIT, PLEKHA5, RBP7, VGLL3, AASS, DKK1, KRT8, CHSY3, PTN, SLC7A2, ADRB1, TGFA, HSPB8, ATP7B, PCDH19, SLC18B1, ESM1, MAGEC2, ARHGAP42, ZNF462, SLC16A7, TMEM5, SOCS2, SYBU, MFAP5, GPC4, KHDRBS3, CHMP4C, AMPH, ST8SIA4, RGS2, LINC01234, SLAIN1, KCNQ3, TMEM246, ST3GAL1, GHR, ZNF711, LAMA1, PLEKHG3, ITPR2, ZNF518B, DOCK4, WISP3, SERPINE2, NFXL1, PLCXD2, ZNF350, MLKL, DLL1, ZNF331, DMKN, FAM171B, RPS6KA6, PDGFRL, KIAA1551, ZDHHC15, MYH2, NCBP3, BRAP, SOX7, PELP1, IL4R, HPD, STAC, METTL7B, IFI44, APBB2, SPOUT1, ENDOD1, HBEGF, MPP5, ESF1, MCM9, JAG1, SERPINB7, CYB5R2, MATR3, ANO5, CTNS, MOB3B, GFRA1, CCDC181, KIAA1671, EBI3, BEX5, KBTBD8, CD163L1, CASP4, LOC729732, RRAGD, CPNE8, ANKRD1, ITGA2, STK38L, TSR1, DGKI, TEX10, SWI5, HRK, TOX2, ZNF547, ZNF615, LOC400043, INTS6, CKB, GBP3, CCDC3, PRKAR2B, MBOAT1, ZNF708, RBBP6, SH3GL3, IL13RA1, PSMB8, ITGBL1, CEP126, RAP1GAP2, GLT8D2, ZNF605, CEP290, IL15RA, ZNF107, ZNF286A, PREX1, RNF125, SP110, ZNF267, PKP2, C11orf70, LIMCH1, NAV3, MBNL3, AKAP9, TMEM156, EHD1, MAP3K14, TBC1D30, CCDC85C, CHST2, LMO2, INPP4B, TMEM133, ERVMER61--1, ZNF91, CDK9, ZNF492, HMGN5, SEMA3A, MANSC1, IGFBP2, ELOVL4, UPP1, RNF175, ASAP1-IT1, LY6K, SLC2A13, LOC100506691.

###### 

Top thirty enriched GO terms of DEGs in BC according to *P* value.

  Term         Description                                                     Count   Genes
  ------------ --------------------------------------------------------------- ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO:0005615   Extracellular space (CC)                                        67      NRP1, IL18, EDN1, CXADR, MMP2, ASAH1, CKB, ESF1, GPC4, SERPINE2, WISP3, ANG, PAPPA, HTRA1, IL4R, HMOX1, CCBE1, TGFBI, CFH, TGFA, IL15RA, PDGFC, CAT, SEMA3A, LOXL2, EBI3, MTUS1, GHR, INHBB, VEGFC, VEGFA, SERPINB7, STC1, VCAN, CTSB, CA2, ADAMTS5, CXCL1, WNT5A, CCL2, ENPP2, TNC, CXCL3, CLU, CXCL2, CD109, CXCL8, KIT, NRN1, CCL7, VCAM1, ENO2, COL6A2, PTN, GCNT1, COL18A1, LGALS1, NLGN1, CHI3L2, PXDNL, DKK3, LAMA1, AFP, DKK1, HBEGF, IGFBP2, PLAU
  GO:0007157   Heterophilic cell-cell adhesion via plasma membrane cell (BP)   10      VCAM1, PTPRD, CADM1, TENM2, TENM3, NLGN1, NECTIN3, CDH2, CXADR, IL1RAPL1
  GO:0071356   Cellular response to tumor necrosis factor (BP)                 14      VCAM1, PID1, HDAC4, CCL2, EDN1, CXCL8, NKX3-1, FABP4, HAS2, RORA, ANKRD1, ADAMTS12, ZNF268, CCL7
  GO:0071456   Cellular response to hypoxia (BP)                               13      SLC8A1, EPAS1, CPEB2, EDN1, RORA, ANKRD1, HMOX1, VEGFA, BNIP3L, PTN, NKX3-1, NDRG1, STC1
  GO:0004896   Cytokine receptor activity (MF)                                 8       IL4R, LIFR, IL15RA, IL13RA1, IL11RA, EBI3, GHR, IL31RA
  GO:0050839   Cell adhesion molecule binding (MF)                             10      VCAM1, PTPRD, CADM1, TENM2, TENM3, NLGN1, DSP, NECTIN3, ITGA4, CXADR
  GO:0006695   Cholesterol biosynthetic process (BP)                           8       MSMO1, INSIG2, SQLE, DHCR7, INSIG1, LSS, FDFT1, DHCR24
  GO:0001666   Response to hypoxia (BP)                                        16      CAV1, CCL2, EPAS1, ITGA2, MMP2, DDIT4, ITPR2, VCAM1, VEGFC, CA9, ANG, HMOX1, VEGFA, CAT, LOXL2, PLAU
  GO:0030198   Extracellular matrix organization (BP)                          17      RECK, COL18A1, HAPLN1, COL13A1, TNC, ITGA2, ITGA4, NID2, DDR2, COL5A1, VCAM1, LAMA1, TGFBI, COL6A2, VCAN, APBB2, MFAP5
  GO:0014704   Intercalated disc (CC)                                          8       SLC8A1, PGM5, ANK2, PKP2, GJA1, DSP, CDH2, CXADR
  GO:0001525   Angiogenesis (BP)                                               18      SAT1, COL18A1, CAV1, NRP1, CCL2, EPAS1, IL18, CXCL8, RORA, JAG1, ESM1, MMP2, VEGFC, ANG, HMOX1, VEGFA, TGFBI, TGFA
  GO:0007155   Cell adhesion (BP)                                              28      CCL2, TNC, CDH2, DDR2, ITGBL1, VCAM1, WISP3, TGFBI, COL6A2, ROBO2, LOXL2, COL18A1, HAPLN1, NLGN1, CD99, ITGA2, PTPRS, CHST4, NECTIN3, ITGA4, NID2, COL5A1, LAMA1, NCAM2, PGM5, CNTN1, VCAN, ADAM12
  GO:0005604   Basement membrane (CC)                                          10      P3H2, COL18A1, LAMA1, TNC, TGFBI, PTN, EFNA5, NID2, LOXL2, COL5A1
  GO:0060326   Cell chemotaxis (BP)                                            9       CXCL1, VCAM1, CCL2, CXCL2, FPR1, HBEGF, LPAR1, KIT, DOCK4
  GO:0030165   PDZ domain binding (MF)                                         10      ADRB1, ATP2B4, CADM1, SNTB1, NLGN1, GJA1, LPAR1, CXADR, SDC2, DOCK4
  GO:0008284   Positive regulation of cell proliferation (BP)                  27      TNC, EDN1, ESM1, KIT, HMGN5, IL31RA, AKR1C3, TGFA, PTN, NKX3-1, PDGFC, ZNF268, RUNX2, COL18A1, LIFR, DLL1, IRS1, TNS3, VEGFC, HDAC4, VEGFA, KDM4C, HBEGF, PBX1, HAS2, GRK5, F2R
  GO:0071347   Cellular response to interleukin-1 (BP)                         9       CCL2, EDN1, CXCL8, NKX3-1, HAS2, RORA, ANKRD1, ADAMTS12, CCL7
  GO:0003779   Actin binding (MF)                                              19      ABLIM1, DIXDC1, PHACTR1, MLPH, MICAL2, MYH2, MICAL3, PXK, MYO9A, EPB41L3, EPS8, ANG, LIMCH1, SNTB1, TMOD2, WIPF1, ADD3, STK38L, MYLK
  GO:0005886   Plasma membrane (CC)                                            145     CADM1, JAG1, LPAR1, MMP2, KANK1, IL31RA, PRKAR2B, ATP2B4, ANK2, HTRA1, TGFBI, IL15RA, RRAS, PDGFC, MLKL, PAG1, MTUS1, EBI3, RECK, CA12, LIFR, PTPRS, ABCC10, DLL1, BASP1, IRS1, IL11RA, NCAM2, CD163L1, IGSF3, DSP, EFNA5, ADD3, WNT5A, SLC2A13, IL1R1, CAV1, ENPP2, CSMD3, MME, BDKRB1, PXK, NRN1, PAQR5, P2RY8, PPP1R16A, NDRG1, TBC1D30, RAP1GAP2, LRFN5, CDC42EP3, IL1RAPL1, MSMO1, ADGRG6, ITGA2, ITGA4, PCDH19, DOCK4, RGS2, SLC7A2, PKP2, RGS4, SYTL2, MARCKS, GRK5, DNAJB4, PLAU, CACNA1A, NRP1, PREX1, GJA1, GABBR2, CXADR, DDR2, SDC2, GPC4, SPRY1, SLC1A3, KCNQ3, HMOX1, GUCY1A2, TGFA, MGLL, ANO5, CAT, IL13RA1, JPH1, SLC1A1, ATP8B3, GHR, PTGER4, MICAL3, MPP5, NECTIN3, ALDH3B1, DAPK1, EPB41L3, ADRB1, CA9, STXBP6, CD82, CNTN1, CA2, ADAM12, ARL4C, PMEPA1, PTCHD1, SLC39A10, FPR1, CD109, CDH2, KIT, PLPP3, VCAM1, PLIN2, CLEC2B, DNER, ENO2, CERK, VMP1, EHD1, SLC39A4, FAM127A, PTPRD, SLC8A1, COL13A1, MAP1B, NLGN1, LY6K, CD99, DGKI, ANXA3, ITPR2, KCNN4, DKK1, PLSCR4, SLC16A7, FYN, BNC2, TENM2, GFRA1, HBEGF, CTNS, F2R, VLDLR
  GO:0009986   Cell surface (CC)                                               29      WNT5A, IL1R1, NRP1, CLU, CD109, LPAR1, CXADR, SDC2, VCAM1, KCNQ3, SLC1A3, TGFA, PTN, ROBO2, PDGFC, HHIP, LRFN5, IL1RAPL1, GHR, LGALS1, NLGN1, ITGA2, LY6K, ITGA4, VEGFA, IGSF3, HBEGF, PLAU, F2R
  GO:0019221   Cytokine-mediated signaling pathway (BP)                        12      CCL2, SOCS2, LIFR, IL15RA, KIT, LRRC15, IL13RA1, IL17RD, IL11RA, EBI3, GHR, IL31RA
  GO:0007165   Signal transduction (BP)                                        52      NRP1, PPARG, IQGAP3, GJA1, IL17RD, DDR2, ANK2, STAC, WISP3, IL4R, INTS6, GUCY1A2, IL15RA, PDE8A, PAG1, SH3GL3, ARHGAP28, OPTN, IRS1, DAPK1, VEGFC, INPP4B, CXCL1, CCL2, GULP1, FPR1, CXCL8, AKAP9, KIT, SP110, CXXC5, MYO9A, CCL7, PDE1A, ARHGAP42, CDC42EP3, IL1RAPL1, EPAS1, LGALS1, DPYSL5, DPYSL2, ITPR2, MGST3, RPS6KA6, EPS8, TENM2, TENM3, HBEGF, IGFBP2, PLCXD2, PLAU, VLDLR
  GO:0009612   Response to mechanical stimulus (BP)                            8       INHBB, CCL2, PTGER4, TNC, JUND, PPARG, BDKRB1, IGFBP2
  GO:0005578   Proteinaceous extracellular matrix (CC)                         18      WNT5A, COL18A1, HAPLN1, LTBP1, LGALS1, MMP2, COL5A1, GPC4, LAMA1, WISP3, CCBE1, VEGFA, TGFBI, COL6A2, VCAN, ADAMTS12, TFPI2, ADAMTS5
  GO:0030426   Growth cone (CC)                                                11      NRP1, EPS8, ANG, PREX1, TENM2, TMOD2, DPYSL2, BASP1, APBB2, CXADR, NEFL
  GO:0005518   Collagen binding (MF)                                           8       TGFBI, CCBE1, ADGRG6, ITGA2, NID2, CTSB, LRRC15, DDR2
  GO:0007399   Nervous system development (BP)                                 19      CXCL1, GDA, MAP1B, DPYSL5, NLGN1, MBD5, DPYSL4, JAG1, DPYSL2, NRN1, HDAC4, ST8SIA4, VEGFA, TMOD2, PTN, GFRA1, EFNA5, SIM1, VLDLR
  GO:0005515   Protein binding (MF)                                            282     PRR16, LTBP1, CADM1, TUBB2A, EDN1, RORA, LPAR1, MXI1, MAGEC2, ATP2B4, FLI1, SERPINE2, STAC, INSIG2, CCBE1, INSIG1, INTS6, CFH, CEP290, CCNA1, SH3GL3, RECK, MYH2, LIFR, PTPRS, PRKCDBP, OPTN, BRAP, VEGFC, SPAG4, AAMDC, VEGFA, TGIF1, ADAMTS5, RBP7, IL1R1, TADA3, CCDC92, TAF9B, MME, BDKRB1, RIMS2, MYO9A, PPP1R3C, SYBU, GYS1, TCF4, RAP1GAP2, IL1RAPL1, GCNT1, KLF6, KLF12, KLF13, LGALS1, SMAD6, LAMA1, EPS8, RGS2, PKP2, SYTL2, GRK5, PLAU, NRP1, PPARG, GJA1, RNF182, CKB, FAM168A, SWI5, ZNF350, DMKN, IL4R, TGFA, NEURL1B, HHIP, IL13RA1, BHLHE41, GHR, SH3PXD2A, SNAPC3, TLE4, NECTIN3, RNF175, RBBP6, INHBB, EPB41L3, VCAN, TMSB4X, G0S2, MAP3K14, ARL4C, THAP8, CEP126, CXCL2, FPR1, CXCL8, ZNF365, KIT, MLF1, AMPH, PLEKHG4, COL6A2, ETV1, HBP1, VMP1, WIPF1, CERK, FAM127B, SLC8A1, PDK3, DGKI, NID2, MID1, SNAI2, AFP, DKK1, PLSCR4, FYN, BNIP3L, RASSF2, GFPT2, SH3RF3, PBX1, APBB2, KATNAL1, NR5A2, TEX10, VLDLR, LMO2, CHMP4C, IL18, LMO4, ANKRD1, JAG1, MMP2, KANK1, PRKAR2B, GSTM4, ANK2, ELOVL4, TGFBI, RRAS, IL15RA, ROBO2, MLKL, PDGFC, EBI3, PAG1, NCBP3, TMPRSS15, PID1, SOCS2, HRK, DLL1, BASP1, URB1-AS1, IRS1, TNS3, MAP4K4, HSPB8, TNFAIP8, DSP, RIPK4, GBP3, WNT5A, CAV1, CLU, RRAGA, SOX7, CXXC5, RRAGD, CCL7, PAQR5, PEG10, PELP1, PPP1R16A, CDYL2, JUND, NKX3-1, NDRG1, MBNL3, RUNX2, STK38L, ARHGDIB, REEP6, DIXDC1, EPAS1, RFX5, ITGA2, ITGA4, SELENOM, PSMB8, SREBF2, DOCK4, HDAC4, NREP, PLEKHA5, PRICKLE1, TXNDC16, SLAIN1, PNRC1, BEX5, PTTG1IP, DNAJB4, MYLK, CACNA1A, ATP7B, SAT1, IER3, FOSL2, CYB5R2, MLPH, ATL1, PREX1, GABBR2, CXADR, DDR2, SDC2, SAP30, FAM133A, SPRY1, ANG, HMOX1, TRIM6, SNTB1, MOB3B, TUBA1A, LOXL2, SLC1A1, KHDRBS3, PTGER4, MPP5, CDK9, ALDH3B1, DAPK1, FAM134B, EYA1, ADRB1, PPM1E, CA8, CD82, ZNF711, CLDN1, INPP4B, CTSB, CA2, MATR3, PMEPA1, ABLIM1, PPP4R4, NANOS1, AKAP9, CDH2, GRAMD3, MAP3K7CL, PLPP3, TSC22D1, DNER, KRT8, LACC1, ENO2, SEC22C, ADAMTS12, PIK3R3, EHD1, NEFL, SCO2, PTPRD, COL13A1, MAP1B, DPYSL5, DPYSL4, DPYSL2, RCAN3, PPP1R13L, MGST3, IRF9, ATXN1, KCNN4, ID2, IGFBP2, F2R
  GO:0031012   Extracellular matrix (CC)                                       19      COL18A1, HAPLN1, LTBP1, LGALS1, TNC, CLU, NID2, MMP2, COL5A1, LAMA1, SERPINE2, HTRA1, TGFBI, COL6A2, DSP, VCAN, ADAMTS12, LOXL2, TFPI2
  GO:0008201   Heparin binding (MF)                                            13      CCL2, NRP1, COL13A1, CCL7, COL5A1, SERPINE2, ANG, WISP3, VEGFA, CFH, PTN, HBEGF, ADAMTS5

###### 

Top fifteen significant signaling pathways associated with DEGs in BC according to *P* value.

  ID         Term                                              Count   *P* value   Genes
  ---------- ------------------------------------------------- ------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------
  hsa00100   Steroid biosynthesis                              6       0.000342    MSMO1, **SQLE**, DHCR7, **LSS**, **FDFT1**, DHCR24
  hsa04514   Cell adhesion molecules (CAMs)                    12      0.005828    VCAM1, NCAM2, CADM1, CLDN1, NLGN1, CNTN1, CD99, VCAN, NECTIN3, ITGA4, CDH2, SDC2
  hsa04540   Gap junction                                      9       0.007066    ADRB1, TUBB2A, GUCY1A2, TUBAL3, GJA1, PDGFC, **LPAR1**, **TUBA1A**, ITPR2
  hsa04060   Cytokine-cytokine receptor interaction            15      0.015894    IL1R1, CCL2, IL18, LIFR, CXCL8, KIT, IL11RA, CCL7, VEGFC, IL4R, VEGFA, IL15RA, PDGFC, IL13RA1, GHR
  hsa00910   Nitrogen metabolism                               4       0.015944    CA9, CA8, CA12, CA2
  hsa05202   Transcriptional misregulation in cancer           12      0.019138    EYA1, FLI1, ID2, LMO2, PPARG, CXCL8, **CDK9**, ETV1, PBX1, RUNX2, PLAU, MLF1
  hsa04668   TNF signaling pathway                             9       0.020338    **CXCL1**, VCAM1, CCL2, **CXCL3**, EDN1, **CXCL2**, MLKL, MAP3K14, PIK3R3
  hsa04974   Protein digestion and absorption                  8       0.022588    **COL18A1**, KCNN4, SLC8A1, **COL13A1**, **COL6A2**, MME, SLC1A1, **COL5A1**
  hsa05412   Arrhythmogenic right ventricular cardiomyopathy   7       0.025957    PKP2, GJA1, DSP, ITGA2, ITGA4, CDH2, TCF7L1
  hsa04151   PI3K-Akt signaling pathway                        19      0.028358    TNC, ITGA2, **LPAR1**, KIT, ITGA4, IRS1, **COL5A1**, DDIT4, LAMA1, VEGFC, IL4R, VEGFA, GYS1, **COL6A2**, EFNA5, PDGFC, PIK3R3, GHR, F2R
  hsa04510   Focal adhesion                                    13      0.033173    CAV1, TNC, ITGA2, ITGA4, **COL5A1**, VEGFC, LAMA1, **FYN**, VEGFA, **COL6A2**, PDGFC, PIK3R3, MYLK
  hsa04150   mTOR signaling pathway                            6       0.037778    RPS6KA6, RRAGA, RRAGD, PIK3R3, IRS1, DDIT4
  hsa05219   Bladder cancer                                    5       0.041527    VEGFA, CXCL8, HBEGF, MMP2, DAPK1
  hsa05200   Pathways in cancer                                20      0.047909    WNT5A, EPAS1, PTGER4, PPARG, CXCL8, ITGA2, **BDKRB1**, **LPAR1**, KIT, MMP2, TCF7L1, DAPK1, LAMA1, VEGFC, VEGFA, TGFA, NKX3-1, HHIP, PIK3R3, F2R
  hsa04630   Jak-STAT signaling pathway                        9       0.048544    IRF9, SOCS2, IL4R, LIFR, IL15RA, PIK3R3, IL13RA1, IL11RA, GHR

The bold represented the key genes in the modules.

###### 

Twelve module networks analyzed by MCODE.

  Cluster   Score   Nodes   Edges   Node IDs
  --------- ------- ------- ------- ---------------------------------------------------------------------------
  1         8       8       28      **CXCL2**, **CXCL1**, IL8, GABBR2, FPR1, **BDKRB1**, **LPAR1**, **CXCL3**
  2         6       6       15      SEMA3A, DPYSL4, DPYSL5, DPYSL2, **FYN**, NRP1
  3         5.6     6       14      **COL6A2**, P4HA2, **COL18A1**, **COL13A1**, **COL5A1**, LEPREL1
  4         5       5       10      **TUBA1A**, OPTN, AKAP9, CEP290, PRKAR2B
  5         4       4       6       **FDFT1**, SREBF2, **SQLE**, **LSS**
  6         4       4       6       SNAPC3, INTS6, **CDK9**, ELL2
  7         4       4       6       FBXL7, RBBP6, RNF182, KBTBD8
  8         3.5     5       7       TRIM6, IRF9, MID1, TRIM2, GBP3
  9         3.143   8       11      WNT5A, SH3GL3, KIT, CLU, VEGFC, TMSB4X, DNAJC6, AMPH
  10        3       3       3       TUBB2A, TUBAL3, GJA1
  11        3       3       3       NEURL1B, DLL1, JAG1
  12        3       3       3       GSTM4, MGST3, EPHX1

The bold represented the key genes in the modules.

[^1]: Academic Editor: Senthamil R. Selvan
